Vietnam Tightens IP Customs Enforcement for E-commerce Imports
Vietnam Tightens IP Customs Enforcement for E-commerce Imports: New rules from March 2026 target medical devices, B2C platforms & live-streamed sales—act now to avoid delays.
Time : Jun 01, 2026

Vietnam’s customs authorities have expanded intellectual property (IP) enforcement to include cross-border e-commerce channels, effective March 1, 2026. The new regulation—Ministry of Finance Circular No. 06/2026/TT-BTC—grants customs the authority to proactively suspend clearance of suspected infringing goods and explicitly brings B2C platforms, express courier services, and live-streamed sales under formal IP monitoring. This development is particularly relevant for medical device importers, distributors, and e-commerce operators handling high-value items such as imaging equipment, ultrasound probes, and diagnostic instruments.

Event Overview

Effective March 1, 2026, Vietnam’s Ministry of Finance issued Circular No. 06/2026/TT-BTC, authorizing customs officials to initiate ex officio suspension of customs clearance for goods suspected of infringing intellectual property rights. For the first time, the circular formally includes cross-border B2C e-commerce platforms, international express shipments, and live-streamed sales within the scope of IP-related customs supervision. The regulation applies to all imported goods entering Vietnam, with no exemptions for low-value or consumer-facing parcels.

Industries Affected

Direct Importers & Overseas Distributors

These entities are directly responsible for customs declarations and IP compliance documentation. Under the new framework, they face heightened risk of shipment delays or detention if trademark, patent, or design rights related to their products are not pre-registered with Vietnamese customs. Medical device models—including ultrasound probes and imaging systems—often involve complex, layered IP portfolios, increasing scrutiny likelihood.

E-commerce Platform Operators & Local Importers

Local e-commerce importers acting as consignees or fulfillment partners must now ensure upstream IP documentation is traceable and verifiable. Unlike traditional import models, platform-based B2C flows often lack centralized brand authorization records, making real-time verification difficult. Live-streamed sales—where product claims may outpace official licensing—pose additional compliance exposure.

Supply Chain & Logistics Service Providers

Fulfillment centers, bonded warehouses, and express couriers handling medical device imports are now subject to secondary liability checks. While not directly liable for IP infringement, their operational records—including origin declarations, supplier attestations, and packaging labels—may be requested during customs investigations, affecting processing timelines and service reliability.

What Enterprises and Practitioners Should Focus On Now

Verify and update IP recordal status with Vietnam Customs

Overseas rights holders and their local representatives must confirm whether trademarks, patents, or industrial designs covering medical devices are officially recorded in Vietnam’s IP Customs Recordation System. Unrecorded rights cannot trigger ex officio suspension—and therefore offer no procedural protection against counterfeit diversion or parallel imports.

Map and document end-to-end supply chain provenance for high-risk categories

For ultrasound probes, imaging systems, and other regulated medical hardware, importers should compile verifiable evidence of authorized manufacturing, distribution agreements, and original equipment manufacturer (OEM) relationships. Customs may request this documentation on short notice; pre-assembled dossiers reduce clearance uncertainty.

Review B2C platform terms, labeling practices, and live-sale disclosures

Claims made on e-commerce listings or during live streams—such as ‘original’, ‘certified’, or ‘genuine’—must align with documented IP ownership or licensing. Discrepancies may be treated as evidence of intent to deceive, triggering deeper review even without a formal complaint.

Monitor implementation guidance from Vietnam Customs and the National Office of Intellectual Property

Circular No. 06/2026/TT-BTC sets the legal foundation but does not specify inspection frequency, risk-scoring criteria, or appeal procedures. Official FAQs, enforcement bulletins, or pilot program announcements—expected in Q2 2026—will clarify operational thresholds and priority categories.

Editorial Perspective / Industry Observation

Observably, this policy shift signals Vietnam’s institutional alignment with WTO TRIPS-plus enforcement norms—not yet a fully matured system, but one moving decisively toward proactive, channel-agnostic IP oversight. Analysis shows that the inclusion of B2C and live commerce reflects recognition of structural shifts in import patterns, rather than an isolated crackdown. From an industry perspective, the circular functions less as an immediate operational constraint and more as a formalized accountability mechanism: it elevates documentation rigor from a best practice to a prerequisite for predictable market access. Current enforcement intensity remains uneven across ports and product categories, suggesting phased rollout rather than uniform application.

Conclusion

This regulation marks a structural recalibration—not merely a procedural update—in how Vietnam governs IP-sensitive imports via digital trade channels. It does not ban unlicensed imports outright, nor does it replace civil litigation or administrative complaints. Rather, it introduces a customs-level gatekeeping function where documentation quality, supply chain transparency, and platform governance collectively determine clearance efficiency. For stakeholders, the current posture is better understood as a compliance inflection point: preparation now reduces friction later, but overreaction—such as halting shipments pending full system maturity—is unwarranted.

Source Attribution

Main source: Vietnam Ministry of Finance Circular No. 06/2026/TT-BTC, effective March 1, 2026. Implementation details—including risk assessment methodology, priority product lists, and appeal mechanisms—remain pending official clarification and are subject to ongoing observation.